Poststreptococcal acute glomerulonephritis can be a risk factor for accelerating kidney dysfunction in Alport syndrome: a case experience.
Yoshinori ArakiAzusa KawaguchiNana SakakibaraYoshinobu NagaokaTomohiko YamamuraTomoko HorinouchiChina NaganoNaoya MorisadaKazumoto IijimaKandai NozuPublished in: CEN case reports (2020)
Alport syndrome (AS) is a progressive kidney disease. Male cases with X-linked AS (XLAS) are reported to develop end-stage kidney disease (ESKD) at the age of around 20-30 years. One risk factor for developing ESKD at a young age is a genotype of having truncating variants in the COL4A5 gene. However, to date, other such factors have remained unclear. Here, we describe a 15-year-old Japanese boy with XLAS who had a missense variant in the COL4A5 gene. He presented with gross hematuria, severe proteinuria, oliguria, systemic edema, body weight gain, and hypertension after pharyngitis. Blood examination showed kidney dysfunction, hypocomplementemia, and elevated antistreptolysin-O level. We diagnosed him with poststreptococcal acute glomerulonephritis (PSAGN) and he was stopped treatment by lisinopril, and received supportive treatment. However, he showed an unusual clinical course for PSAGN and, consequently, developed ESKD 15 months after the onset of PSAGN without recovery from the kidney dysfunction. This case showed that the onset of PSAGN can be a risk factor for AS patients to develop ESKD at a young age.
Keyphrases
- weight gain
- liver failure
- copy number
- body mass index
- oxidative stress
- end stage renal disease
- drug induced
- blood pressure
- respiratory failure
- ejection fraction
- newly diagnosed
- case report
- genome wide
- multiple sclerosis
- chronic kidney disease
- birth weight
- prognostic factors
- gene expression
- weight loss
- peritoneal dialysis
- early onset
- dna methylation
- combination therapy
- intellectual disability
- mechanical ventilation
- smoking cessation